A Phase 2, Randomized, Partially Blinded, Active-Controlled Study Assessing the Efficacy and Safety of Variable Anticoagulation Reversal Using the REG1 System in Patients With Acute Coronary Syndromes: Results of the RADAR Trial

Study Questions:

What is the degree of anticoagulation reversal required to mitigate bleeding, and the feasibility of using pegnivacogin (REG1) to prevent ischemic events in acute coronary syndrome (ACS) patients managed with an early invasive approach?